# Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.

> **NCT06912815** · NA · RECRUITING · sponsor: **Xiang Gao** · enrollment: 184 (estimated)

## Conditions studied

- Crohn Disease (CD)

## Interventions

- **BIOLOGICAL:** ustekinumab and semi enteral nutrition
- **OTHER:** Exclusive enteral nutrition

## Key facts

- **NCT ID:** NCT06912815
- **Lead sponsor:** Xiang Gao
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-09
- **Final completion:** 2026-09
- **Target enrollment:** 184 (ESTIMATED)
- **Last updated:** 2025-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06912815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06912815, "Ustekinumab With Semi-EN vs Exclusive EN for Preoperative Crohn's Disease Optimization.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06912815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*